CY1108690T1 - Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων - Google Patents

Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων

Info

Publication number
CY1108690T1
CY1108690T1 CY20091100016T CY091100016T CY1108690T1 CY 1108690 T1 CY1108690 T1 CY 1108690T1 CY 20091100016 T CY20091100016 T CY 20091100016T CY 091100016 T CY091100016 T CY 091100016T CY 1108690 T1 CY1108690 T1 CY 1108690T1
Authority
CY
Cyprus
Prior art keywords
arylopyrrolidines
substituted
androgen receptor
compound
formula
Prior art date
Application number
CY20091100016T
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Douglas Richard Stack
Ian Roger Clemens
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1108690T1 publication Critical patent/CY1108690T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση του τύπου: Τύπος I ή ένα φαρμακευτικά αποδεκτό άλας της- φαρμακευτικές συνθέσεις που περιλαμβάνουν μία αποτελεσματική ποσότητα μιας ένωσης του τύπου I σε συνδυασμό με ένα κατάλληλο φορέα, αραιωτικό, ή έκδοχο- και μεθόδους για την θεραπευτική αντιμετώπιση των φυσιολογικών διαταραχών, ιδιαίτερα της αδυναμίας, της οστεοπόρωσης, της οστεοπενίας, και της αρσενικής και της θηλυκής σεξουαλικής δυσλειτουργίας που περιλαμβάνουν την χορήγηση σε έναν ασθενή σε ανάγκη της μιας αποτελεσματικής ποσότητας μιας ένωσης του τύπου I.
CY20091100016T 2005-05-13 2009-01-09 Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων CY1108690T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68091105P 2005-05-13 2005-05-13
EP06759481A EP1891038B1 (en) 2005-05-13 2006-05-10 Substituted n-arylpyrrolidines as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
CY1108690T1 true CY1108690T1 (el) 2014-04-09

Family

ID=37057376

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100016T CY1108690T1 (el) 2005-05-13 2009-01-09 Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων

Country Status (17)

Country Link
US (1) US7807691B2 (el)
EP (1) EP1891038B1 (el)
JP (1) JP5089578B2 (el)
CN (1) CN101175747B (el)
AT (1) ATE412647T1 (el)
AU (1) AU2006247738A1 (el)
BR (1) BRPI0610183A2 (el)
CA (1) CA2608419A1 (el)
CY (1) CY1108690T1 (el)
DE (1) DE602006003432D1 (el)
DK (1) DK1891038T3 (el)
ES (1) ES2314922T3 (el)
MX (1) MX2007014053A (el)
PL (1) PL1891038T3 (el)
PT (1) PT1891038E (el)
SI (1) SI1891038T1 (el)
WO (1) WO2006124447A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5070054B2 (ja) * 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
US8013008B2 (en) 2006-11-30 2011-09-06 Takeda Pharmaceutical Company Limited Cyclic amine compound
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY159910A (en) 2007-08-07 2017-02-15 Takeda Pharmaceuticals Co Pyrrolidin-2-one derivatives as androgen receptor modulator
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009133861A1 (ja) * 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US9102671B2 (en) * 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
CA2890905A1 (en) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
RS64115B1 (sr) 2014-03-28 2023-04-28 Univ Duke Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20220035276A (ko) 2016-06-22 2022-03-21 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
CA3047411A1 (en) 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
EP4218934A1 (en) 2018-10-05 2023-08-02 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN114746400A (zh) * 2019-11-20 2022-07-12 南京明德新药研发有限公司 用作选择性雄激素受体调节剂的化合物
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2003254993A1 (en) 2002-08-12 2004-03-03 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
US7495016B2 (en) * 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
US20060148893A1 (en) * 2003-06-10 2006-07-06 Blanc Jean-Baptiste E Chemical compounds

Also Published As

Publication number Publication date
MX2007014053A (es) 2008-02-05
CA2608419A1 (en) 2006-11-23
CN101175747A (zh) 2008-05-07
AU2006247738A1 (en) 2006-11-23
US20080176864A1 (en) 2008-07-24
EP1891038B1 (en) 2008-10-29
CN101175747B (zh) 2011-06-22
JP5089578B2 (ja) 2012-12-05
BRPI0610183A2 (pt) 2012-12-04
WO2006124447A2 (en) 2006-11-23
ES2314922T3 (es) 2009-03-16
JP2008540554A (ja) 2008-11-20
PT1891038E (pt) 2008-12-02
EP1891038A2 (en) 2008-02-27
DK1891038T3 (da) 2009-01-19
PL1891038T3 (pl) 2009-04-30
WO2006124447A3 (en) 2007-03-29
SI1891038T1 (sl) 2009-04-30
DE602006003432D1 (de) 2008-12-11
US7807691B2 (en) 2010-10-05
ATE412647T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
DE602006012322D1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MY151295A (en) Pyrimidyl indoline compound
TW200626158A (en) Naphthaline derivatives
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EA201490573A1 (ru) Соединение бензотиазолона
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
ATE522537T1 (de) (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
ITMI20042187A1 (it) Derivati isossazolici per allievare il dolore neiropatico
UA93951C2 (ru) Производные 2-пиридинкарбоксамида b качестве модуляторов натриевых каналов